Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Recruiting · NCT05817214 · Registry updated 2024-04-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2024-04-19 | NCT05817214 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Akeso Biopharma Co., Ltd. | 3 |
| Zhongnan Hospital | 74 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhongnan Hospital of Wuhan University | Wuhan | China | 65 |